Dr. Pedro Barata discusses the positive impact of cabozantinib+nivolumab treatment for high-risk patients with advanced renal cell carcinoma, including subgroups of patients with liver, lung, or bone metastases.
Dr. Vincent Xu discusses the safety and tolerability outcomes from the CheckMate-9ER trial,...
PLAY
Dr. Vincent Xu discusses the safety and tolerability outcomes from the CheckMate-9ER trial,...
PLAY
Dr. Pedro Barata discusses the positive impact of cabozantinib+nivolumab treatment for high-risk patients...
PLAY
Dr. Yasser Ged discusses five-year follow-up data from the CheckMate-9ER trial, which studied...
PLAY
Dr. Michael Devitt discusses the efficacy of cabozantinib as a first- and second-line...
PLAY©2025 Oncology Matrix. All Rights Reserved.
